ArticleThe Lancet. Global health2023
Prioritising respiratory syncytial virus prevention in low-income and middle-income countries.
Article in The Lancet. Global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- RSV-associated acute otitis media in children under five years old: a systematic review and meta-analysis.Journal of global health · 2026Pooled it
- Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2024Pooled it
- Multiple co-infections and risk of severe outcomes in children with respiratory syncytial virus infection.BMC infectious diseases · 2026Article
- A White Paper on Advancing Long-Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation.Clinical pharmacology and therapeutics · 2026Review
- Article
- Global, regional, and national burden of upper respiratory infections in adolescents and young adults: an analysis of the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner.Human vaccines & immunotherapeutics · 2025Review
- Genomic characterization and phylogenetic analysis of respiratory syncytial virus F gene in Sri Lanka: a comparative study.BMC genomic data · 2025Article
- Global Trends and Attributable Risk Factors in the Disease Burden of Lower Respiratory Infections.Tropical medicine and infectious disease · 2025Article
- Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021.American journal of respiratory and critical care medicine · 2025Article
- Proof-of-principle of a technology transfer of a dried blood virus neutralisation assay to a Gavi-eligible country.BMJ global health · 2025Article
- Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt.The Lancet regional health. Europe · 2023Article
- Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic.JAMA network open · 2023Article
- The road to approved vaccines for respiratory syncytial virus.NPJ vaccines · 2023Review
- Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.